SMMT Stock Skyrocketed 194.27%

$Summit Therapeutics (SMMT.US)$
Why: Summit Therapeutics announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific antibody ivonescimab. And Akeso is a pioneer and source originator in developing innovative antibodies.
The agreement supports Summit’s mission of developing and commercializing groundbreaking oncology pipeline products aimed at improving the quality of life of patients with serious unmet medical needs. For Akeso, the deal represents an opportunity to introduce its highly innovative antibodies to markets, including the U.S., Canada, Europe, and Japan – an important step towards Akeso’s strategic intent of becoming a global biopharma organization.